| Document |
Document Title |
|
WO/2022/204429A1 |
Microglia are an essential part of the immune system in the central nervous system, as well as potential sources of disease. Gene silencing employs short interfering RNA (siRNA) to selectively target genes that are the source of such dis...
|
|
WO/2022/200857A1 |
The present disclosure relates to a. compound of formula I or a. pharmaceutically acceptable salt thereof Formula I wherein A is Formula II X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, 4-8 m...
|
|
WO/2022/202761A1 |
[Problem] To provide a peptide complex capable of binding to c-Met protein. [Solution] Provided is a peptide complex containing a peptide A, in which the peptide A is a peptide comprising the amino acid sequence represented by X1-X2-X3-V...
|
|
WO/2022/202403A1 |
Provided is a material that is useful for increasing the Neisseria mucosa content in the oral cavity. This oral Neisseria-mucosa-increasing agent has, as active ingredients, a nitrate-ion-supplying compound and one or more sugar alcoho...
|
|
WO/2022/203384A1 |
The present invention may provide information relating to an appropriate injection amount, of magnetic cells injected into the body, which is required to achieve a desired strain rate in a target tissue. Further, a composition comprising...
|
|
WO/2022/203543A1 |
The invention relates to the field of gerontology, and more particularly to the possibility of acting on the expression profile of certain genes in human blood plasma which are associated with biological aging by administering an amarant...
|
|
WO/2022/198438A1 |
Disclosed are ligand-bound zinc sulfide nanoparticles, the method of preparing the ligand-bound zinc sulfide nanoparticles, composition containing ligand-bound zinc sulfide nanoparticles, uses of ligand-bound zinc sulfide nanoparticles a...
|
|
WO/2022/203547A1 |
The invention relates to medicine, and more particularly to midwifery, and is intended for treating gestosis in the first trimester of pregnancy. For treating gestosis in the first trimester of pregnancy, the use of a phospholipid emulsi...
|
|
WO/2022/203571A1 |
The invention relates to a combination comprising an effective amount of dextran sulfate, or a pharmaceutically acceptable salt thereof, and an effective amount of heparin, or a pharmaceutically acceptable salt thereof, for use in treatm...
|
|
WO/2022/201775A1 |
An intestinal bacteria count reducing agent according to one aspect of the present invention contains silicon particles or silicon fine particles and reduces the number of intestinal bacteria. By using this intestinal bacteria count redu...
|
|
WO/2022/200608A1 |
The present invention relates to composition comprising at least a compound having general formula (I) for use in (i) increasing resistance to age-related pathologies, (ii) improving a physiological state or disorder related to cell agei...
|
|
WO/2022/204369A1 |
This disclosure relates to messenger RNA (mRNA) therapy for the treatment of methylmalonic acidemia. mRNAs for use in the invention, when administered in vivo, encode methylmalonyl-CoA mutase. mRNA therapies of the disclosure increase an...
|
|
WO/2022/204517A1 |
This disclosure relates to formulations containing arginine and other ingredients useful in managing acute and chronic complications of coronavirus infections, including respiratory symptoms fatigue, hypercoagulable state, cardiac sympto...
|
|
WO/2022/202864A1 |
The present invention relates to: a compound, or a pharmacologically acceptable salt thereof, that has GLP-1 receptor agonist activity and that is useful as an agent for treating or preventing diseases involving the GLP-1 receptors; and ...
|
|
WO/2022/201832A1 |
The present invention addresses the problem of providing a novel GLP-1 secretion promotion agent. The present invention provides a GLP-1 secretion promotion agent that includes a GPR84 agonist as an active ingredient.
|
|
WO/2022/202947A1 |
Disclosed is a stable aqueous pharmaceutical composition or freeze-dried pharmaceutical composition that comprises a protein as an active ingredient. This pharmaceutical composition comprises a protein having a physiological activity and...
|
|
WO/2022/202714A1 |
The purpose of the present invention is to provide skin care focusing on the sense of touch. It was found that sandalore and an analog thereof have an action of activating Merkel cells. Provided is a Merkel cell activator containing sand...
|
|
WO/2022/204331A1 |
The present application provides methods and processes for making and using a composition comprising a branched KGF-2 peptide, as well as methods for treating ocular conditions and/disorders with the branched KGF-2 peptide described herein.
|
|
WO/2022/201644A1 |
[Problem] To search for compounds capable of suppressing TMPRSS2 expression in a cell or in tissue. [Solution] Expression of TMPRSS2 in a cell or in tissue is suppressed by 5-aminolevulinic acids.
|
|
WO/2022/203379A1 |
The present invention relates to a composition for enhancing efficacy of lactic acid bacteria. More specifically, the composition contains at least two branched-chain amino acids selected from the group consisting of leucine, isoleucine,...
|
|
WO/2022/202241A1 |
An inhibitor of UV-induced DNA damage is provided. This inhibitor of UV-induced DNA damage contains a Albizia julibrissin bark extract.
|
|
WO/2022/199603A1 |
An antibody fusion protein comprising: i) a multivalent (e.g., bivalent) antibody or antigen-binding fragment thereof specifically recognizing Angiopoietin-2 (Ang2) ( "multivalent anti-Ang2 antibody or antigen-binding fragment thereof" )...
|
|
WO/2022/204463A1 |
Provided herein are compositions and methods useful for improving or increasing weight gain or growth velocity in a subject, e.g., an infant having or suspected of having failure to thrive. In some aspects, the methods are or include adm...
|
|
WO/2022/196816A1 |
Provided are a colicin-fighting monoclonal antibody molecule or a derivative thereof, and a pharmaceutical composition containing the same, for ameliorating acute lung injury and acute worsening of pulmonary fibrosis. The pharmaceutica...
|
|
WO/2022/195451A1 |
Redox-active compound or a pharmaceutically acceptable salt thereof for use in the method for treating a disease selected from among the diseases due to dysfunction of the mitochondrial respiratory chain complexes I, II, III. This redox-...
|
|
WO/2022/195113A1 |
The present invention relates to the mesenchymal stem cells and their use in modulating the immune response following transplantation.
|
|
WO/2022/194267A1 |
A GPR84 antagonist, and a preparation method therefor and a use thereof, specifically a compound represented by formula (I), and a tautomer, stereoisomer, hydrate, solvate, pharmaceutically acceptable salt, or prodrug thereof. The compou...
|
|
WO/2022/195119A1 |
The present invention relates to the field of stem cells and their use in processing ex vivo samples (e.g. blood samples). More specifically, the present invention relates to the use of mesenchymal stem cells in ECMO.
|
|
WO/2022/195963A1 |
The present invention provides: an agent for inhibiting microglial M1 polarization, the agent containing a substance that inhibits the expression of an inhibitor of nuclear factor kappa B kinase subunit epsilon (IKBKE) or inhibits kinase...
|
|
WO/2022/196719A1 |
The present invention provides: a chimeric receptor polypeptide which is useful in treatment of myasthenia gravis and in which an extracellular domain that includes an antigenic region linkable to an anti-human nicotinic acetylcholine re...
|
|
WO/2022/196668A1 |
The present invention provides a novel nucleic acid that suppresses the expression of ITGAV. The present invention indicates that a nucleic acid for a specific target sequence or a nucleic acid having a specific sequence has an excellent...
|
|
WO/2022/192964A1 |
The present invention provides methods for treating or preventing aggression, agitation, irritability and/or anger in a subject comprising administering to a subject in need thereof a therapeutically effective amount of a compound of For...
|
|
WO/2022/197627A1 |
The present disclosure provides methods of treating coronavirus-associated diseases in an individual comprising administering to the individual an effective amount of nevirapine and an effective amount of valacyclovir and/or nevirapine. ...
|
|
WO/2022/198099A1 |
Compositions of polynucleotide(s) are disclosed. A polynucleotide may encode for a polypeptide, protein, or functional fragment thereof associated with primary ciliary dyskinesia (PCD). Pharmaceutical compositions, kits, and methods for ...
|
|
WO/2022/197641A1 |
The present invention relates to 1H-pyrazolo[3,4-d]pyrimidin-6-yl- amine derivatives of formula (I) as hematopoietic progenitor kinase 1 (HPK1) modulators and/or inhibitors for the treatment of cancer and other diseases, such as e.g. vir...
|
|
WO/2022/196609A1 |
It is found that phenylbutyric acid (PBA) can prevent progressive retinal photoreceptor cell death and can prevent the deterioration in a visual function. On the basis of these findings, a pharmaceutical composition for preventing retina...
|
|
WO/2022/195102A1 |
The present invention relates to a compound having the following formula (I) wherein: - R and R' are, independently from each other, H or (C1-C6)alkyl groups, or form together with the carbon atoms carrying them a (C6-C10)aryl group; - R...
|
|
WO/2022/190317A1 |
[Problem] To provide a novel interferon production promoter. [Solution] A type-I and/or type-III interferon production promoter containing, as an active ingredient, Clostridium butyricum or a culture thereof.
|
|
WO/2022/191184A1 |
The present invention pertains to: a ghrelin receptor sensitivity-enhancing agent that contains ornithine or a salt thereof as an active ingredient; a composition that contains ornithine or a salt thereof as an active ingredient and that...
|
|
WO/2022/191107A1 |
The present invention provides a polymer represented by formula (I) etc., said polymer being useful as a drug carrier for effectively delivering a drug to a target site. (In the formula, each symbol is as defined in the description.)
|
|
WO/2022/190072A1 |
The present invention relates to an iron-based formulation and compositions thereof for use in a method for the treatment of a gastrointestinal inflammation, in a therapeutic or non-therapeutic treatment of an iron deficiency by administ...
|
|
WO/2022/191194A1 |
One of the problems addressed by the present invention is the provision of an agent for inhibiting renal damage induced by rhabdomyolysis. The present invention uses cilastatin or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/191183A1 |
The present invention relates to a composition that includes an intestinal bacterium belonging to the genus Veillonella having an inflammation-suppressing action or a substance having an inflammation-suppressing action derived from said ...
|
|
WO/2022/192562A1 |
The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of USP30, and the treatment of USP30-mediated disorders.
|
|
WO/2022/191182A1 |
The present invention pertains to: a composition that comprises an intestinal bacterium belonging to the phylum Bacteroides and having an inflammation reducing effect or a substance derived from the intestinal bacterium and having an inf...
|
|
WO/2022/191092A1 |
The present invention addresses the problem of providing a new method for increasing the intracerebral histamine concentration. The present invention provides a compound represented by general formula (I) or a salt thereof. [In the formu...
|
|
WO/2022/191320A1 |
The present invention addresses the problem of providing a technique for further promoting the proliferation of a plurality of major species of bacteria belonging to the genus Bifidobacterium in the intestinal flora. Oligosaccharides inc...
|
|
WO/2022/192745A1 |
Disclosed are compounds of Formula IIA, IIA-1, IIB, IIB-1, IIC and IIC-1: and pharmaceutical compositions and methods of use thereof These compounds inhibit Protein Arginine M-Methyl Transferase 5 (PRMT5) activity and are useful in metho...
|
|
WO/2022/191673A1 |
The present invention relates to a pharmaceutical composition for preventing or treating liver fibrosis, wherein the pharmaceutical composition contains exosomes surface-modified with vitamin A as active ingredients. The exosomes surface...
|
|
WO/2022/192163A1 |
The present invention discloses a recombinant adenovirus vector of a replication-defective human adenovirus (HAdv85C5) or a bovine adenovirus (BAdv85C5) comprising a recombinant adenovirus vector having a heterologous DNA segment encodin...
|
